Research-Driven, Research-Ready
Next-Generation Imaging for Preclinical Discoveries
At Quantum Sense, we craft versatile SPECT devices for preclinical research, combining innovation and dedication to empower scientists in uncovering molecular insights, accelerating discoveries, and shaping the future of medicine with bold aspirations and unwavering humility.
Innovating Preclinical Imaging: The Power of Miniature SPECT
We envision a transformative leap in preclinical imaging with our compact, highly versatile SPECT technology. Rooted in the high-precision VIP (Versatile Imaging Particle) scanner, our devices integrated cutting edge semiconductor detector technology to enable spectral imaging capabilities. This innovation allows researchers to harness novel theragnostic tracers like 177Lu and 225Ac, opening new dimensions in oncologic therapy.
Why preclinical SPECT? The demands of modern research require tools that are versatile, efficient, and user-friendly. Our devices deliver high 3D and energy resolution, ensuring clarity in the most complex isotope combinations. By extracting the maximum information from each detected radioactive decay, they redefine and enable new imaging protocols. Moreover, their compact design and ease of use make them accessible to laboratories with diverse scales, democratizing advanced nuclear imaging technology.
The limitations in spatial and energy resolution in current preclinical SPECT technologies often hinder the ability to discern between different spectral layers, reducing image quality and potential to apply dosimetry measurements.
The advent of theragnostic agents in nuclear medicine has brought new tracers, both clinically available and currently under development, with new energy levels and branching ratios, posing a need for a shift in preclinical imaging technology.
The varying task-dependent needs call for imaging systems able to provide outstanding performance in multiple domains, such as high-resolution anatomical imaging, accurate quantification of tracer distribution, and precise dosimetry.
Over 70% of drug candidates fail in preclinical trials due to insufficient molecular insights...
What if you could change that?
Quantum Sense is driven by a multidisciplinary team of innovators and experts in nuclear imaging, committed to redefining preclinical diagnostics through cutting-edge technology and visionary leadership.
Mokhtar Chmeissani
Inventor of Quantum Sense's first patent and a seasoned expert in imaging technologies with over 30 years in high-energy physics.
Gerard Ariño
Specialist in nuclear medicine imaging and detector technology, driving innovation at Quantum Sense.
Diego Torres
Tech entrepreneur with 20+ years of experience in business strategy and technological development, leading Quantum Sense’s vision.
Discover how Quantum Sense can empower your research
Innovation Meets Precision
Compact and Powerful Solutions
Real-Time Insights
Sustainable Research
Shaping the Future of Molecular Imaging
Join us in revolutionizing preclinical research and diagnostics with state-of-the-art solutions designed for innovation and impact.
Let’s innovate together—reach out to learn more.
Discover how Quantum Sense can empower your research.
